Gardasil Update

Merck may seek approval to sell Gardasil for new uses.
The AP (2/17) reports that a new study shows that Merck's "Gardasil is about 89 percent effective in blocking cervical cancer, genital warts and lingering HPV infections in women aged 24 to 45." Another new study "shows it is about 77 percent effective in blocking anal cancer and precancerous lesions in homosexual men." The drugmaker plans to "seek approval to sell the vaccine for those uses."